Nitrobenzyl phosphorodiamidates as potential hypoxia-selective alkylating agents

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Developing novel chemotherapeutic agents is crucial for cancer treatment.
• Targeting hypoxic tumor microenvironments offers a strategy to overcome drug resistance.
• Phosphorodiamidates represent a class of compounds with potential anticancer activity.

Purpose of the Study:

• To synthesize and evaluate the cytotoxicity of novel nitrobenzyltetrakis(chloroethyl)phosphorodiamidates.
• To assess the selective toxicity of these compounds against HT-29 cells under aerobic and hypoxic conditions.
• To investigate the mechanism of action, including DNA interstrand cross-linking.

Main Methods:

• Synthesis of nitrobenzyltetrakis(chloroethyl)phosphorodiamidate analogs.
• Cytotoxicity assays using HT-29 cells and murine bone marrow progenitor cells.
• Spheroid model and alkaline elution experiments to assess DNA damage.

Main Results:

• All compounds exhibited selective toxicity towards HT-29 cells under hypoxia (selectivity ratios 1.6 to >90).
• Compounds lacking nitro or chloroethyl groups were not cytotoxic, confirming the importance of both moieties.
• Cytotoxicity increased with depth in HT-29 spheroids, indicating preferential hypoxic activity.
• Hypoxic cells showed significantly more DNA interstrand cross-links than aerobic cells, comparable to melphalan.

Conclusions:

• Novel nitrobenzylphosphorodiamidates are selectively toxic to hypoxic cancer cells.
• The observed cytotoxicity is attributed to DNA interstrand cross-linking mediated by alkylation.
• These compounds hold promise as hypoxia-activated prodrugs for cancer therapy.